NEW YORK (GenomeWeb News) — Merck has licensed RNAi technology from Protiva Biotherapeutics, and Protiva has agreed to drop ongoing litigation against the drug maker’s subsidiary Sirna Therapeutics, Protiva said this week.
 
Merck will use Protiva’s stable nucleic acid-lipid particles, or SNALP, technology in its pharmaceutical-development programs, Protiva said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.